Physician profile
Nathan E Chamberlain
NPI 1134126246
$1,237.54
in general payments reported to CMS, 2019-2025
21 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $123 · 2021: $196 · 2022: $171 · 2023: $128 · 2024: $112 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478 · Education: $2.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.27 |
| Education | $2.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $320.12 | 2021-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals Lp | $256.08 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $92.00 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $88.66 | 2022-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $53.98 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $47.96 | 2022-2025 | Terlivaz, Acthar |
| Travere Therapeutics, INC. | $47.50 | 2024-2025 | Filspari |
| Janssen Pharmaceuticals, INC | $44.67 | 2019 | |
| Amgen INC. | $44.33 | 2019-2022 | |
| Lilly USA, LLC | $39.23 | 2024 | Jardiance |
| Akebia Therapeutics INC | $39.04 | 2019-2021 | |
| Genzyme Corporation | $27.72 | 2025 | |
| Calliditas Therapeutics US INC. | $18.00 | 2025 | Tarpeyo |
| Novo Nordisk INC | $16.00 | 2025 | Ozempic |
| Genentech USA, INC. | $15.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $14.91 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.86 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2020 | |
| Horizon Therapeutics Plc | $14.31 | 2022 | |
| Opko Pharmaceuticals, LLC | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.